Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 401–500 of 1,003
Appetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity
Gan, H.-W., Cerbone, M., & Dattani, M. T. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad033 · Cited by 65
Impact of oxygen availability on body weight management
Quintero, P., Milagro, F. I., Campión, J., & Martínez, J. A. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.10.022 · Cited by 78
“This protein inhibits food intake and reduces the feeling of hunger in the postpandrial state [41–43].”
BackgroundLiraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice
Tamura, K., Minami, K., Kudo, M., Iemoto, K., Takahashi, H., & Seino, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126003 · Cited by 70
“In addition, GLP-1 slows gastric emptying [4] and reduces appetite [5], which have”
BackgroundKořínková, L., Pražienková, V., Černá, L., Karnošová, A., Železná, B., Kuneš, J., & Maletínská, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597583 · Cited by 81
The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
Mells, J., & Anania, F. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358527 · Cited by 70
Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.09.001 · Cited by 85
Morbid Obesity and Sleeve Gastrectomy: How Does It Work?
Papailiou, J., Albanopoulos, K., Toutouzas, K. G., Tsigris, C., Nikiteas, N. I., & Zografos, G. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0148-5 · Cited by 82
“Furthermore, GLP-1 has been also shown to promote satiety and decrease energy intake through its interaction with its receptors in the brain [80, 81 ].”
BackgroundHughes, G. M., Boyland, E. J., Williams, N. J., Mennen, L. I., Scott, C. E., Kirkham, T. C., Harrold, J. A., Keizer, H. G., & Halford, J. C. G. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-6 · Cited by 73
Cummings, B. P., Stanhope, K. L., Graham, J. L., Baskin, D. G., Griffen, S. C., Nilsson, C., Sams, A., Knudsen, L. B., Raun, K., & Havel, P. J. (2010) · Diabetes · doi:10.2337/db09-1564 · Cited by 72
“GLP-1 signaling increases satiety (6,7) and slows gastric motility and secretion, further contributing to a reduction in food intake (8).”
BackgroundBifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller-Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 68
“This has been confir ed on animal models [42–45], as well as in various human populations, including lean individuals [46,47] and individuals with obesity [48–51].”
BackgroundAoun, L., Almardini, S., Saliba, F., Haddadin, F., Mourad, O., Jdaidani, J., Morcos, Z., Al Saidi, I., Bou Sanayeh, E., Saliba, S., et al. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100333 · Cited by 56
“It does this by activating GLP-1 receptors, which reduces food intake, body weight, and stimulates insulin secretion in a glucose-dependent manner [6].”
BackgroundInteractions between gastric emptying and satiety, with special reference to glucagon-like peptide-1
Hellström, P. M., & Näslund, E. B. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00618-7 · Cited by 78
Kumar, M., Hunag, Y. P., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302836 · Cited by 72
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 72
Intravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men
Brennan, I. M., Otto, B., Feltrin, K. L., Meyer, J. H., Horowitz, M., & Feinle‐Bisset, C. (2006) · Peptides · doi:10.1016/j.peptides.2006.10.014 · Cited by 74
Can Gut Hormones Control Appetite and Prevent Obesity?
Chaudhri, O. B., Wynne, K., & Bloom, S. R. (2008) · Diabetes Care · doi:10.2337/dc08-s269 · Cited by 84
Liu, H., Hu, Y., Simpson, R. W., & Dear, A. E. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0387 · Cited by 67
Intestinal GLP-1 and satiation: from man to rodents and back
Steinert, R. E., Beglinger, C., & Langhans, W. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.172 · Cited by 78
Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Fu, Z., Gilbert, E. R., & Liu, D. (2012) · Current Diabetes Reviews · doi:10.2174/15733998130104 · Cited by 471
Brennan, I. M., Feltrin, K. L., Horowitz, M., Smout, A. J. P. M., Meyer, J. H., Wishart, J., & Feinle-Bisset, C. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00732.2004 · Cited by 68
“9 pmol kg 1 min (1)) we used was comparable to that in previous studies (9, 14, 24) and resulted in slightly supraphysiological plasma levels, compared with those observed in response to a meal or duodenal nutrient infusion (5, 31).”
BackgroundMethodInfluentialVagal mediation of GLP-1's effects on food intake and glycemia
Krieger, J.-P., Langhans, W., & Lee, S. J. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.001 · Cited by 67
Uzoigwe, C., Liang, Y., Whitmire, S., & Paprocki, Y. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01053-7 · Cited by 62
“GLP-1 RAs have been shown to have a number of beneficial physiological effects, including the glucose-dependent stimulation of insulin secretion from beta cells [2], inhibition of glucagon secretion [2], slowed gastric emptying [3], and increased satiety [4].”
BackgroundGut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
“Of importance, GLP-1 has been shown to have a central effect to promote satiety, to reduce appetite and food intake [28], and GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
BackgroundNielsen, M. S., Ritz, C., Wewer Albrechtsen, N. J., Holst, J. J., le Roux, C. W., & Sjödin, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa061 · Cited by 65
Self-citationBajaj, H. S., Venn, K., Ye, C., Patrick, A., Kalra, S., Khandwala, H., Aslam, N., Twum-Barima, D., & Aronson, R. (2017) · Diabetes Care · doi:10.2337/dc16-1582 · Cited by 65
Borer, K. T., Wuorinen, E., Ku, K., & Burant, C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2495 · Cited by 66
“First Published Online April 28, 2009 Abbreviations: CCK, Cholecystokinin; EX, exercise; FFA, nonesterified fatty acid; GIP, glucose insulinotropic peptide; GLP-1, glucagon-like peptide-1; SED, sedentary; TPN, iv nutrient replacement; VO2max, maximum oxygen uptake.”
BackgroundInfluentialYoun, Y. S., Chae, S. Y., Lee, S., Jeon, J. E., Shin, H. G., & Lee, K. C. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.09.013 · Cited by 65
“[6] Flint A, Raben A, Astrup A, Holst JJ.”
BackgroundPeripheral signalling involved in energy homeostasis control
Lancha, A., Frühbeck, G., & Gómez‐Ambrosi, J. (2012) · Nutrition Research Reviews · doi:10.1017/s0954422412000145 · Cited by 74
Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor
Holst, J. J., & Madsbad, S. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.02.033 · Cited by 67
“[15] Flint A, Raben A, Astrup A, Holst JJ.”
BackgroundResultSelf-citationEndogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Diamant, M., & Ijzerman, R. G. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0461 · Cited by 66
Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
Torekov, S. S., Madsbad, S., & Holst, J. J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00860.x · Cited by 65
“Several studies have shown that peripheral infusions of GLP-1 significantly and dose-dependently enhance satiety and reduce food intake in normal subjects (7,35).”
BackgroundSelf-citationLow‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects
Chapman, I., Parker, B., Doran, S., Feinle‐Bisset, C., Wishart, J., Lush, C. W., Chen, K., LaCerte, C., Burns, C., McKay, R., et al. (2007) · Obesity · doi:10.1038/oby.2007.626 · Cited by 64
Obesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64
Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03451.x · Cited by 65
Seghieri, G., Anichini, Cosimi, S., Carlo, D., Bellis, D., Franconi, Orsini, P., & Baccetti (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s42729 · Cited by 63
Therapeutic advances in obesity management: an overview of the therapeutic interventions
Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., Ambi, A. M., Abdalla, M. A., Al‐Mulla, F., Abu‐Farha, M., & Abubaker, J. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1364503 · Cited by 77
The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon‐like peptide‐1 release
Ong, W., Gribble, F., Reimann, F., Lynch, M., Houslay, M., Baillie, G., Furman, B., & Pyne, N. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00194.x · Cited by 66
“GLP-1 also suppresses gastric motility (Nauck et al., 1997), promotes satiety (Flint et al., 1998) and may possess insulinomimetic actions on glucose disposal (Egan et al., 2002).”
BackgroundCombining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Holst, J. J., & Vilsbøll, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01628.x · Cited by 63
“In addition, whereas DPP-4 inhibitors are weight-neutral [55], GLP-1RAs promote weight loss [13]; a possible explanation for this is that GLP-1RAs slow gastric emptying and increase satiety [60], while DPP-4 inhibitors lower the concentrations of active PYY 3-36, another important gastrointestinal-derived inhibitor of…”
BackgroundSelf-citationYasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., & Tanaka, I. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.064964 · Cited by 65
Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., & Campbell, R. K. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m134 · Cited by 63
GLP-1: A Mediator of the Beneficial Metabolic Effects of Bariatric Surgery?
Manning, S., Pucci, A., & Batterham, R. L. (2015) · Physiology · doi:10.1152/physiol.00027.2014 · Cited by 63
Raben, A., Holst, J. J., Madsen, J., & Astrup, A. V. (2001) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.177 · Cited by 66
Self-citationBergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62
“GLP-1 furthermoreacts as a satiety-promoting hormone (4), and GLP-1 receptor (GLP-1R) agonists with plasmaglucose–loweringandbodyweight– reducing effects have been developed for thetreatmentof type2diabetesandobesity.”
BackgroundMethodSelf-citationGuerrero-Hreins, E., Goldstone, A. P., Brown, R. M., & Sumithran, P. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110303 · Cited by 62
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“High postprandial GLP-1 secretion is bene fi cial for insulin-dependent glucose control and appetite inhibition and satiety, facilitating its use for the prevention and treatment of OW [86,87].”
BackgroundSelf-citationEffects of food form on appetite and energy balance
Dhillon, J., Running, C. A., Tucker, R. M., & Mattes, R. D. (2015) · Food Quality and Preference · doi:10.1016/j.foodqual.2015.03.009 · Cited by 69
Prevention and Treatment of Type 2 Diabetes in Youth
Libman, I. M., & Arslanian, S. A. (2006) · Hormone Research in Paediatrics · doi:10.1159/000095981 · Cited by 82
Olli, K., Salli, K., Alhoniemi, E., Saarinen, M., Ibarra, A., Vasankari, T., Rautonen, N., & Tiihonen, K. (2015) · Nutrition Journal · doi:10.1186/1475-2891-14-2 · Cited by 59
“When administered experimentally to humans it can suppress energy intake, promote satiety and decrease hunger [17,18].”
BackgroundA brief review of salient factors influencing adult eating behaviour
Emilien, C. H., & Hollis, J. (2017) · Nutrition Research Reviews · doi:10.1017/s0954422417000099 · Cited by 71
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Geloneze, B., de Lima-Júnior, J. C., & Velloso, L. A. (2017) · Drugs · doi:10.1007/s40265-017-0706-4 · Cited by 60
“[42] demonstrated in healthy volunteers that infusion of native GLP-1 during breakfast increased satiety and fullness and reduced the caloric intake in the next meal by 12%.”
BackgroundVallöf, D., Vestlund, J., & Jerlhag, E. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.020 · Cited by 61
“The brains were cut in 50 μm sections, and the location of the probe and/or guide cannulas were verified (Franklin and Paxinos, 1996; Paxinos and Watson, 1998).”
InfluentialObesity pharmacotherapy: What is next?
Colon-Gonzalez, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.005 · Cited by 62
“Administration of GLP-1 in animals and humans induces satiety and weight loss (Flint et al., 1998; Meeran et al., 1999; Naslund et al., 2004; Turton et al., 1996).”
BackgroundPalladino, A. A., Sayed, S., Levitt Katz, L. E., Gallagher, P. R., & De León, D. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1263 · Cited by 61
“the central appetite suppressive effects of GLP-1 (19, 20), its”
BackgroundMerani, S., Truong, W., Emamaullee, J. A., Toso, C., Knudsen, L. B., & Shapiro, A. M. J. (2008) · Endocrinology · doi:10.1210/en.2008-0501 · Cited by 61
“Because liraglutide and other GLP-1 analogs are known to induce satiety (28, 29), we sought to investigate further whether the reduced TTN in liraglutide-treated animals was simply due to reduced food intake and/or reduced body weight in liraglutide-treated animals.”
BackgroundBojanowska, E., & Stempniak, B. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00119-1 · Cited by 65
Sandberg, J. C., Björck, I., & Nilsson, A. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151985 · Cited by 73
Scrocchi, L. A., Hill, M. E., Saleh, J., Perkins, B., & Drucker, D. J. (2000) · Diabetes · doi:10.2337/diabetes.49.9.1552 · Cited by 61
“The administration of GLP-1 to human subjects via peripheral infusion (5), or to rodents via intracerebroventricular (ICV) injection (4), induces satiety and reduces food intake and body weight, respectively.”
BackgroundPinelli, N. R., & Hurren, K. M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q024 · Cited by 59
GLP‐1 and Appetite Responses to a Meal in Lean and Overweight Adolescents Following Exercise
Chanoine, J., Mackelvie, K. J., Barr, S. I., Wong, A. C. K., Meneilly, G. S., & Elahi, D. H. (2008) · Obesity · doi:10.1038/oby.2007.39 · Cited by 59
“Administration of GLP-1 causes an acute increase in satiety and decrease in food intake in normal weight subjects (2,14) as well as in overweight subjects with type 2 diabetes (13).”
BackgroundDietary lipids with potential to affect satiety: Mechanisms and evidence
Maher, T., & Clegg, M. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1423277 · Cited by 67
“The satiating effects of PYY have already been mentioned, and GLP-1 similarly enhances satiety via a delay in gastric emptying (Flint et al. 1998; Shah and Vella 2014).”
BackgroundBradley, D. P., Kulstad, R., & Schoeller, D. A. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.008 · Cited by 64
“[44], who found increased feelings of satiety and fullness and reduced feeling of hunger after intravenous administration of GLP-1.”
BackgroundMeier, J. J., Gallwitz, B., & Nauck, M. A. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00002 · Cited by 67
Complications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 65
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
“[72] Flint A, Raben A, Astrup A, Holst JJ.”
BackgroundOh, D. Y., & Walenta, E. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00115 · Cited by 75
“Proc Natl Acad Sci U S A (2006) 103(44):16454–9.”
BackgroundAlves, M. G., Jesus, T. T., Sousa, M., Goldberg, E., Silva, B. M., & Oliveira, P. F. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151209151550 · Cited by 67
Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males
Jeibmann, A., Zahedi, S., Simoni, M., Nieschlag, E., & Byrne, M. M. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01542.x · Cited by 57
Presence and dynamics of leptin, GLP‐1, and PYY in human breast milk at early postpartum
Schueler, J., Alexander, B. M., Hart, A. M., Austin, K. J., & Larson‐Meyer, D. E. (2013) · Obesity · doi:10.1002/oby.20345 · Cited by 57
Steinert, R. E., Feinle‐Bisset, C., Geary, N., & Beglinger, C. (2013) · Journal of Animal Science · doi:10.2527/jas.2012-6022 · Cited by 67
“In humans, an early report by Flint et al. (1998) indicated that GLP-1 infusions enhanced fullness and reduced energy intake during an ad libitum test meal.”
BackgroundPASSCLAIM1?Body weight regulation, insulin sensitivity and diabetes risk
Riccardi, G., Aggett, P. J., Brighenti, F., Delzenne, N. M., Frayn, K. N., Nieuwenhuizen, A. G., Pannemans, D. L. E., Theis, S., Tuijtelaars, S., & Vessby, B. O. (2004) · European Journal of Nutrition · doi:10.1007/s00394-004-1202-7 · Cited by 72
GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56
Enteroendocrine cells in terminal ileal Crohn's disease
Moran, G. W., Pennock, J., & McLaughlin, J. T. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.01.013 · Cited by 56
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
Mannucci, E., & Rotella, C. M. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.08.002 · Cited by 59
“GLP-1 infusion in healthy subjects and type 2 diabetic patients suppresses appetite and food intake, inducing weight loss [14,29,30].”
BackgroundKassaian, N., Feizi, A., Rostami, S., Aminorroaya, A., Yaran, M., & Amini, M. (2020) · Nutrition · doi:10.1016/j.nut.2020.110854 · Cited by 64
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U., Holst, J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
“GLP-1 has several actions in the body in relation to glucose regulation and weight control: It increases glucoseinduced insulin secretion, suppresses glucagon secretion (also glucose-dependently), inhibits gastric emptying, reduces appetite and promotes satiety [21].”
Self-citationInventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
“GLP-1 is known to enhance glucose-dependent insulin secretion, improve glucose-dependent suppression of inappropriately high glucagon secretion, slow gastric emptying, and reduce food intake [16-18] in humans.”
BackgroundLiraglutide in clinical practice: dosing, safety and efficacy: Liraglutide in practice
Peterson, G. E., & Pollom, R. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02498.x · Cited by 55
Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
Nakamaru, Y., Hayashi, Y., Ikegawa, R., Kinoshita, S., Madera, B. P., Dave, G., Kawaguchi, A., Davies, M., Mair, S. J., Yamazaki, H., et al. (2013) · Xenobiotica · doi:10.3109/00498254.2013.816891 · Cited by 55
“Despite its unique nature and desirable effects such as the enhancement of pancreatic b-cell mass, inhibition of gastric emptying and reduction of food intake (Buteau et al., 2001; Flint et al., 1998; Wettergren et al., 1993; Xu et al., 1999), the clinical use of GLP-1 is restricted due to its short half-life, caused…”
BackgroundHe, M., Su, H., Gao, W., Johansson, S. M., Liu, Q., Wu, X., Liao, J., Young, A. A., Bartfai, T., & Wang, M.-W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014205 · Cited by 56
“. Glucagon-like peptide-1 (GLP-1), an insulinotropic gastrointestinal peptide produced mainly from intestinal endocrine L-cells, inhibits glucagon secretion, stimulates glucose-dependent insulin production, improves insulin sensitivity, delays gastric emptying as well as increases satiety”
BackgroundLittle, T. J., Feltrin, K. L., Horowitz, M., Smout, A. J. P. M., Rades, T., Meyer, J. H., Pilichiewicz, A. N., Wishart, J. M., & Feinle‐Bisset, C. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00290.2005 · Cited by 66
“The discrepant effects of C12 seen in our study may be attributable to the different patterns of secretion of the gastrointestinal hormones CCK and GLP-1, because intravenous infusion of both CCK and GLP-1 suppress energy intake in humans (13, 17).”
BackgroundEmerging themes in idiopathic intracranial hypertension
Grech, O., Mollan, S. P., Wakerley, B. R., Alimajstorovic, Z., Lavery, G. G., & Sinclair, A. J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10090-4 · Cited by 61
Update on Diabetes in the Elderly and the Application of Current Therapeutics
Mazza, A. D., & Morley, J. E. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.07.007 · Cited by 58
van Eyk, H. J., Paiman, E. H. M., Bizino, M. B., IJzermans, S. L., Kleiburg, F., Boers, T. G. W., Rappel, E. J., Burakiewicz, J., Kan, H. E., Smit, J. W. A., et al. (2020) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.12.005 · Cited by 54
Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients
ten Kulve, J. S., van Bloemendaal, L., Balesar, R., IJzerman, R. G., Swaab, D. F., Diamant, M., la Fleur, S. E., & Alkemade, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3291 · Cited by 54
Integrative role of neuropeptides and cytokines in cancer anorexia–cachexia syndrome
Patra, S. K., & Arora, S. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.12.008 · Cited by 64
Stachowska, E., Portincasa, P., Jamioł-Milc, D., Maciejewska-Markiewicz, D., & Skonieczna-Żydecka, K. (2020) · Nutrients · doi:10.3390/nu12113460 · Cited by 54
“Intestinal bacteria (Lactobacillus and Bifidobacterium genera) have a positive effect on the reduction of the weight through a few mechanisms [45,53,54]: (i) reduction of inflammation and thus improvement of hypothalamic sensitivity to insulin; (ii) biotransformation of primary to secondary bile acids, which play an i…”
BackgroundAdam, T. C. M., Lejeune, M. P. G. M., & Westerterp-Plantenga, M. S. (2006) · British Journal of Nutrition · doi:10.1079/bjn20051614 · Cited by 54
“Many studies so far have been working with GLP-1 infusions, leading to an increase in GLP-1 concentrations up to about 50 pmol/l (Flint et al. 1998).”
Gut hormones as pharmaceuticals
Holst, J. J. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00185-3 · Cited by 65
Self-citationExposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13358 · Cited by 53
Self-citationBrain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Use of satiety peptides in assessing the satiating capacity of foods
Mars, M., Stafleu, A., & de Graaf, C. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.08.033 · Cited by 59
Seimon, R. V., Lange, K. M., Little, T. J., Brennan, I. M., Pilichiewicz, A. N., Feltrin, K. L., Smeets, A. J. P. G., Horowitz, M., & Feinle‐Bisset, C. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.29015 · Cited by 54
“Plasma cholecystokinin, PYY, and GLP-1 concentrations were expressed as AUC (pmol min L21) and plasma concentrations premeal (pmol/L), and for plasma cholecystokinin concentrations, peak concentrations (pmol/L) and the time to peak concentrations (min) were calculated.”
ResultInfluentialAcute Effect of Resistant Starch on Food Intake, Appetite and Satiety in Overweight/Obese Males
Al-Mana, N. M., & Robertson, M. D. (2018) · Nutrients · doi:10.3390/nu10121993 · Cited by 59
“Since GLP-1 has been shown to reduce energy intake, improve the sensation of fullness, and reduce the feelings of hunger in lean and obese subjects [24,40], a lack of increase in the GLP-1 concentration in the present study could explain why subjective feelings of satiety did not improve in the present study.”
ResultPharmacological significance of extra-oral taste receptors
D'Urso, O., & Drago, F. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174480 · Cited by 53
Peripheral signals in the control of satiety and hunger
Drazen, D. L., & Woods, S. C. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200311000-00003 · Cited by 66
Opposite Regulation of Ghrelin and Glucagon-like Peptide-1 by Metabolite G-Protein-Coupled Receptors
Engelstoft, M. S., & Schwartz, T. W. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.07.001 · Cited by 61
Incretins, diabetes, and bariatric surgery: a review
Fetner, R., McGinty, J., Russell, C. D., Pi-Sunyer, X., & Laferrère, B. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.09.001 · Cited by 57
GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat
Bozkurt, A., Näslund, E. B., Holst, J. J., & Hellström, P. M. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00095-2 · Cited by 59
Self-citation
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.